Abstract 1858P
Background
Identifying the patient's discomfort and unmet needs is crucial for providing effective care. However, accurately understanding the patient's discomfort can be challenging due to various limitations in the medical field, and in some cases, their discomfort may be underestimated. To better understand the difficulties faced by cancer patients, we implemented Social Listening to identify areas where improved treatment may be provided.
Methods
From October 1, 2021 to September 30, 2022, we gathered online data related to cancer and anti-cancer treatments. Using NetBase as our social listening platform, we filtered out irrelevant and commercial content from the collected data.
Results
A total of 169,575 social mentions related to cancer and anticancer treatment were collected. Among them, 12% (n=20,899) addressed the challenges experienced by patients following a cancer diagnosis. These challenges were further categorized based on the content of social media posts, with 52% focusing on physical difficulties, 42% on emotional challenges, and 6% on difficulties related to daily life. Emotional difficulties such as worry, denial, depression, fear, and anxiety were prevalent among cancer patients, with variations in priority depending on the time of diagnosis, treatment, and post-treatment stages. Of the 16,743 social media discussions related to cancer care, only 9% were related to managing emotional stress. A majority (84%) of discussions related to mental health management involved receiving psychiatric treatment, with the remaining 16% focusing on self-help groups, communication with others, meditation, hobbies, and religious practices.
Conclusions
Emotional burdens, along with physical difficulties, were frequently discussed on social media. However, there appeared to be a relative lack of focus on the management of emotional burdens. Considering the known association between emotional management and cancer treatment outcomes, it is imperative for physicians to prioritize their patients' emotional well-being and offer appropriate support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Korean Society of Medical Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05